BiotechTube
Home/Pipeline/SB101

SB101

Not Specified

Pre-clinicalActive

Key Facts

Indication
Not Specified
Phase
Pre-clinical
Status
Active
Company
Shift Bioscience

About Shift Bioscience

Shift Bioscience is an early-stage biotech pioneering an AI-powered approach to cellular rejuvenation, aiming to treat age-related diseases by reversing epigenetic aging signatures. Its core technology platform identifies gene targets that safely reverse aging clocks, with a lead program (SB000) targeting age-related hearing loss and a pipeline exploring liver fibrosis and systemic sclerosis. The company operates from Cambridge, UK, and Toronto, Canada, positioning itself at the intersection of computational biology and traditional therapeutic development to address the fundamental biology of aging.

View full company profile

Therapeutic Areas

Age-related Hearing LossLiver FibrosisSystemic Sclerosis

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved